Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACLY | P53396 | 8/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.50 |
| ▸ | RAD52 | P43351 | 1/20 | 0.49 |
| ▸ | FABP4 | P15090 | 3/20 | 0.44 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.43 |
| ▸ | PTGFR | P43088 | 1/20 | 0.42 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.41 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.41 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.41 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25073104 | 0.91 | KDM4E (0.46) | ACLYTDP1RAD52FABP4LRRK2 | |
| SCHEMBL25072736 | 0.90 | ACLY (0.44) | ACLYTDP1RAD52FABP4LRRK2 | |
| SCHEMBL25073362 | 0.88 | ACLY (0.41) | ACLYTDP1RAD52FABP4LRRK2 | |
| SCHEMBL25073454 | 0.88 | KIF11 (0.48) | ACLYRAD52LRRK2CSNK2A2CSNK2A1 | |
| SCHEMBL25073416 | 0.87 | KDM4E (0.43) | ACLYTDP1RAD52CSNK2A2CSNK2A1 | |
| SCHEMBL25073413 | 0.86 | MEN1 (0.42) | ACLYTDP1RAD52LRRK2CSNK2A2 | |
| SCHEMBL25737555 | 0.86 | ACLY (0.42) | ACLYTDP1RAD52FABP4LRRK2 | |
| SCHEMBL25073396 | 0.85 | ACLY (0.43) | ACLYTDP1RAD52LRRK2CSNK2A2 | |
| SCHEMBL25072551 | 0.85 | ACLY (0.43) | ACLYTDP1RAD52LRRK2CSNK2A2 | |
| SCHEMBL25734676 | 0.85 | ACLY (0.39) | ACLYTDP1RAD52LRRK2CSNK2A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230143250-A1 | 17-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 13 INHIBITORS AND METHODS OF USE THEREOF | ENANTA PHARMACEUTICALS, INC. | 2023-05-11 | — | — | US | disclosed |
| US-20230143250-A1 | 17-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 13 INHIBITORS AND METHODS OF USE THEREOF | ENANTA PHARMACEUTICALS, INC. | 2023-05-11 | — | — | US | disclosed |
| WO-2023023310-A1 | 17-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 13 INHIBITORS AND METHODS OF USE THEREOF | ENANTA PHARMACEUTICALS, INC. (US) | 2023-02-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230143250-A1 | 17-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 13 INHIBITORS AND METHODS OF USE THEREOF | HSD17B1, HSD17B13, HSD17B3 | ACLY 421/4885TDP1 3118/4885RAD52 4005/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.